Bristol-Myers doubles down on PsiOxus in $936M-plus “armed” oncolytic virus deal
Bristol-Myers Squibb $BMY is taking its relationship with PsiOxus to the proverbial next level. The big biotech is grabbing rights to the Oxford-based company’s next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
